Member Info for WengerOut

http://www.thebusinessdesk.com/yorkshire/news/2030227-monday-interview-ceo-of-listed-biotech-firm-avacta

It’s already bounced you fool, it closed at 3.17p. Fancy spending your weekend on a bulletin board where you hold no shares, very sad.

But you never know - Commenting on the success of the Placing, Dave Wall, Managing Director of 88 Energy, stated: "We would like to thank our advisers and shareholders for their continued support as we enter a potentially transformational period for the Company, which includes a possible farm-out by year-end followed by the spud of the Winx-1 exploration well in the first quarter of 2019."

Well if you’re listed on the UK stock exchange where your shareholders are predominately British, why would you expect to have the AGM anywhere else?

Great input by the usual non biased regulars, RL, V, CBS and others, always appreciated by those like me that don’t have the technical understanding of such things.

Thanks for this wonderful insight Speedie, after 8 years of holding I’ll contact my broker and dump all my shares straightaway.

https://www.openpr.com/news/1348031/Global-Scaffold-Technology-Market-Key-Information-By-Top-Key-Player-Merck-and-Company-Thermo-Fisher-Scientific-Inc-3D-Biotek-LLC-Pelo-Biotech-GmbH-Corning-Inc-Becton-Dickinson-and-Company-Avacta-Life-Sciences-Limited-Nanofiber-Solutions-NuVasiv.html Competitive Landscape The global scaffold technology market is characterized by the presence of well-diversified international and small and medium-sized vendors. These companies are consistently launching new products to enhance their offerings in the market. With the advancement of technologies, companies are innovating and introducing new customized products to cater the growing needs of the customers. Leading companies are also acquiring other companies, and enhancing their product offerings to improve their market reach. Acquisitions enable key players to increase their market potential in terms of geographic expansion and expansion of customer base

Sure is.... a nice pre Xmas rally with further announcements, I can feel it in my water ;-)

Funny how people can’t spell the word ‘lose’

Twitter - ‪@Blytheweigh ‬

Tim Blyth Twitter Account ‪@TimBlythe1 ‬

Megan Ray and Tim Blyth (Blytheweigh) +44 (0) 20 7138 3203

+7(4212)755615 - he’s only a phone call away!

In the second part of his presentation, Dr Johnson will speak about an innovative class of Affimers that captures antibodies but only when the antibodies are bound to their own targets. This offers a route to improving an important type of diagnostic test to have a more specific and clearer result. The commercial potential for this class of Affimer is significant.

Alastair Smith - “This is another important milestone for Avacta, because it further validates the Affimer technology and our licensing business model. We have built a pipeline of evaluations and collaborations, such as this one with New England Biolabs, to deliver numerous license agreements to commercialise Affimer-based products. Collectively, these royalty bearing licenses will underpin the future high margin revenue from Affimer reagents.”

Hope he/she doesn’t mind me sharing..... I was at the Proactive investor meeting last night and was impressed by the presentation. I was already a shareholder as a result of the recent fund raising but hadn't really looked into the technology as much as I should have done. There are various aspects of the affymer platform which are advantageous. For example the fact that the structure gets around the antibody IP mean that this technology can be used in a variety of beneficial ways. In addition the fact that the reagents used in the diagnostic area are plant based means it is distinctly separate from the therapeutic products. Plus the company is clearly focused on getting deals in the short term. The CEO said a diagnostics deal is imminent and others will follow. And the company is funded into 2020 and that doesn't include any deals in the interim. The key time will be when they get to the first in human studies which will be Q1 next year with the PDL1-LAGS bispecific. Yes I have bought some more this morning via spreadbet.... Nobby

Hi Mostly, all good and news as expected. This company is finally going places, so much in the pipeline in the very near future. I’m expecting many multiples on today’s price within 24 months. Have a listen to the recent CEO interview.

Keep the faith, lots of exciting things about to happen here.

What coincidence that SchachMeister123 and PotatoHead swing from bearish to bullish and back to bearish at exactly the same time. Also what coincidence that they appear on exactly the same stock bulletin boards.

Well Robin has his telephone number at the bottom of each RNS, time we rang him up for some answers +7 (4212) 75 76 15